ABCELLERA BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.76 USD | +3.58% |
|
-2.84% | -34.15% |
| 11/03 | AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases | MT |
| 11/03 | AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,832 | 4,027 | 2,898 | 1,657 | 1,101 | - | - |
| Enterprise Value (EV) 1 | 10,240 | 3,304 | 2,012 | 1,595 | 917.6 | 1,022 | 976.5 |
| P/E ratio | 89.4 x | 29.8 x | 20.3 x | -11.2 x | -6.21 x | -6.04 x | -5.08 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 46.5 x | 10.7 x | 5.97 x | 43.6 x | 23 x | 17.1 x | 13.5 x |
| EV / Revenue | 43.9 x | 8.8 x | 4.14 x | 41.9 x | 19.2 x | 15.9 x | 12 x |
| EV / EBITDA | 63.7 x | 15.1 x | 8.23 x | -7.49 x | -4.22 x | -5.12 x | -3.87 x |
| EV / FCF | 787 x | 17.7 x | 9.73 x | -13.2 x | -5.2 x | -6.53 x | - |
| FCF Yield | 0.13% | 5.63% | 10.3% | -7.58% | -19.2% | -15.3% | - |
| Price to Book | 13.1 x | 3.84 x | 2.36 x | - | - | - | - |
| Nbr of stocks (in thousands) | 2,69,188 | 2,81,581 | 2,86,100 | 2,90,170 | 2,92,782 | - | - |
| Reference price 2 | 40.24 | 14.30 | 10.13 | 5.710 | 3.760 | 3.760 | 3.760 |
| Announcement Date | 29/03/21 | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11.61 | 233.2 | 375.2 | 485.4 | 38.02 | 47.81 | 64.33 | 81.38 |
| EBITDA 1 | - | 160.9 | 218.9 | 244.4 | -212.8 | -217.2 | -199.6 | -252.2 |
| EBIT 1 | - | 156 | 204.4 | 216.5 | -237.2 | -239.7 | -244 | -244.8 |
| Operating Margin | - | 66.92% | 54.48% | 44.6% | -623.82% | -501.27% | -379.37% | -300.77% |
| Earnings before Tax (EBT) 1 | - | 157.8 | 219.1 | 239.1 | -174 | -207.9 | -236.5 | -222.3 |
| Net income 1 | - | 118.9 | 153.5 | 158.5 | -146.4 | -190.3 | -218.6 | -222.3 |
| Net margin | - | 51% | 40.9% | 32.66% | -385% | -398.02% | -339.86% | -273.14% |
| EPS 2 | -0.1500 | 0.4500 | 0.4800 | 0.5000 | -0.5100 | -0.6056 | -0.6229 | -0.7400 |
| Free Cash Flow 1 | - | 13.02 | 186.1 | 206.7 | -120.8 | -176.4 | -156.5 | - |
| FCF margin | - | 5.58% | 49.61% | 42.58% | -317.75% | -368.94% | -243.29% | - |
| FCF Conversion (EBITDA) | - | 8.09% | 85.04% | 84.59% | - | - | - | - |
| FCF Conversion (Net income) | - | 10.95% | 121.29% | 130.39% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 05/10/20 | 29/03/21 | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.508 | 139.3 | 316.6 | 45.92 | 101.4 | 21.54 | 12.19 | 10.06 | 6.599 | 9.2 | 10.85 | 11.52 | 12.04 | 13 | 19.18 |
| EBITDA 1 | -24.43 | 85.53 | 228.9 | -3.499 | 42.88 | -23.96 | -59.36 | - | - | -55.71 | -52.2 | -54.2 | -51.6 | -48.7 | -41.3 |
| EBIT 1 | -28.1 | 81.55 | 225 | -8.396 | 37.74 | -37.78 | -64.87 | -51.39 | -54.89 | -66.05 | -60.25 | -59.83 | -59.08 | -59.25 | -55.57 |
| Operating Margin | -510.09% | 58.53% | 71.06% | -18.29% | 37.22% | -175.34% | -532.1% | -511.03% | -831.79% | -717.97% | -555.14% | -519.46% | -490.61% | -455.87% | -289.72% |
| Earnings before Tax (EBT) 1 | -24.97 | 84.71 | 230.8 | -6.886 | 46.59 | -31.41 | -48.15 | -38 | -39.28 | -48.6 | -51.89 | -52.3 | -51.8 | -52.31 | -55.56 |
| Net income 1 | -21.38 | 59.95 | 168.6 | -6.785 | 26.62 | -29.89 | -40.11 | -30.53 | -28.61 | -47.2 | -48.13 | -48.38 | -47.64 | -49.14 | -55.56 |
| Net margin | -388.16% | 43.03% | 53.25% | -14.78% | 26.26% | -138.75% | -328.99% | -303.58% | -433.55% | -513.04% | -443.39% | -420.06% | -395.55% | -378.03% | -289.71% |
| EPS 2 | -0.0800 | 0.1900 | 0.5400 | -0.0200 | 0.0800 | -0.1000 | -0.1400 | -0.1100 | -0.1000 | -0.1600 | -0.1533 | -0.1467 | -0.1456 | -0.1489 | -0.1450 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 24/02/22 | 10/05/22 | 09/08/22 | 08/11/22 | 21/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 20/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 592 | 723 | 886 | 62.1 | 183 | 79.3 | 124 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | 13 | 186 | 207 | -121 | -176 | -157 | - |
| ROE (net income / shareholders' equity) | - | 28.3% | 16.5% | 14% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | 3.080 | 3.720 | 4.300 | - | - | - | - |
| Cash Flow per Share | - | 0.0900 | 0.7700 | 0.8800 | -0.2000 | - | - | - |
| Capex | - | 9.67 | 58.5 | 70.7 | - | - | - | - |
| Capex / Sales | - | 4.15% | 15.58% | 14.56% | - | - | - | - |
| Announcement Date | 05/10/20 | 29/03/21 | 24/02/22 | 21/02/23 | 20/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.76
USD
Average target price
14.75
USD
Spread / Average Target
+292.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.15% | 1.1B | |
| +1.51% | 42.75B | |
| +49.05% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ABCL Stock
- Financials AbCellera Biologics Inc.
